Skip to content
Life Sciences Series A Founded 2020

Senisca

Developer of senotherapeutics that targets the diseases and signs of ageing. The company develops a new generation of oligonucleotide-based therapies that helps in reversing the aging of old cells and tissues through modulation of RNA splicing. This helps in the restoration of splicing factor levels and reverse senescence. The company was founded in 2020 and headquartered in Exeter, United Kingdom. It has raised $9M…

📍 Exeter, United Kingdom · Genomics,

Funding snapshot

Last roundSeries A
Amount$5M
Date18 March 2024
Total raised$9M
Team size15

About

Developer of senotherapeutics that targets the diseases and signs of ageing. The company develops a new generation of oligonucleotide-based therapies that helps in reversing the aging of old cells and tissues through modulation of RNA splicing. This helps in the restoration of splicing factor levels and reverse senescence. The company was founded in 2020 and headquartered in Exeter, United Kingdom. It has raised $9M in series a funding, with backing from Emerging Longevity Ventures, QantX, R42 Group, Trend Investment Group, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Gene Therapy space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.

Business model

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Emerging Longevity Ventures QantX R42 Group Trend Investment Group APEX Ventures LifeSpan Vision Ventures Longevitytech.fund Gov Trend Exeter Khaghan Notung Investments Tribeca Asset Management Tivoli Group Trend Capital Management

Latest coverage

No articles yet.

Raising like Senisca?

Analyze your pitch deck before your next raise.

Analyze My Deck →